drugset / Trial / NCT00429936

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

NCT00429936 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).

Timeline

Start
2006-12
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator fenretinide Small molecule 100 mg —
Comparator fenretinide Small molecule 300 mg —